Dr Reddy's Laboratories Debt Issuance/Retirement Net - Total 2010-2024 | RDY
Dr Reddy's Laboratories annual/quarterly debt issuance/retirement net - total history and growth rate from 2010 to 2024. Debt issuance/retirement net - total can be defined as the total amount of short term and long term borrowings repaid and issued.
- Dr Reddy's Laboratories debt issuance/retirement net - total for the quarter ending December 31, 2024 was $331M, a 549.02% increase year-over-year.
- Dr Reddy's Laboratories debt issuance/retirement net - total for the twelve months ending December 31, 2024 was $826M, a 462.28% decline year-over-year.
- Dr Reddy's Laboratories annual debt issuance/retirement net - total for 2024 was $0.052B, a 120.97% decline from 2023.
- Dr Reddy's Laboratories annual debt issuance/retirement net - total for 2023 was $-0.248B, a 788.89% decline from 2022.
- Dr Reddy's Laboratories annual debt issuance/retirement net - total for 2022 was $0.036B, a 57.14% decline from 2021.
Dr Reddy's Laboratories Annual Debt Issuance/Retirement Net - Total
(Millions of US $) |
| 2024 |
$52 |
| 2023 |
$-248 |
| 2022 |
$36 |
| 2021 |
$84 |
| 2020 |
$-254 |
| 2019 |
$-220 |
| 2018 |
$13 |
| 2017 |
$252 |
| 2016 |
$-181 |
| 2015 |
$5 |
| 2014 |
$154 |
| 2013 |
$0 |
| 2012 |
$211 |
| 2011 |
$-87 |
| 2010 |
$-79 |
| 2009 |
$-38 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$11.261B |
$3.350B |
|
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
|
